Skip to main content
Livermore
Livermore
ZHEN

Cel Sci Corp

CVM
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000725363

In the last 90 days, Cel Sci Corp insiders filed 1 open-market purchase and 0 sales; 40 institutions reported holding it in 13F filings for Q2 2026, worth $2.08M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Cel Sci Corp changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of CVM: Q1 2023 compared with Q2 2023
MeasureQ1 2023Of which not filed for Q2 2023Q2 2023Change
Holders64261−1
Shares5.64M14.7K5.49M−138.1K (−2.5%)
Value$13.1M$33.7K$13.2M+$177.3K (+1.4%)

2 institutions that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (5)

Institutions that held Cel Sci Corp at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to CVM in Q2 2023
InstitutionSharesValue% of portfolio
Citadel Advisors LLC25,772$62.1K0.00%
Mariner, LLC16,240$39.1K0.00%
Cresset Asset Management, LLC12,376$29.8K0.00%
Rhumbline Advisers1,220$2.94K0.00%
Huntington National Bank500$1.21K0.00%

Sold out (6)

Institutions that held Cel Sci Corp at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of CVM in Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
Verition Fund Management LLC11,600$26.9K
Ingalls & Snyder LLC10,110$23.0K
Quantbot Technologies LP1,118$2.59K
Nisa Investment Advisors, LLC605$1.00K
Advisory Services Network, LLC300$696
AllSquare Wealth Management LLC49$114

Not filed for Q2 2023 yet (2)

Institutions that held Cel Sci Corp at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CVM in Q1 2023 that haven't filed for Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
ETF Managers Group, LLC14,522$33.7K
Householder Group Estate & Retirement Specialist, LLC211$0